Evidence map›Paper›PMID 20717021›Full record

ReviewCurrent opinion in endocrinology, diabetes, and obesity2010

HIV protease inhibitors and obesity.

Erdembileg Anuurad, Andrew Bremer, Lars Berglund

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in endocrinology, diabetes, and obesity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.International journal of molecular sciences · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. A comprehensive diagnostic approach to detect underlying causes of obesity in adults.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2019
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.Best practice & research. Clinical endocrinology & metabolism · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Erdembileg AnuuradDepartment of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Andrew Bremer
Lars Berglund
University of California, Davis · USVA Northern California Health Care System · US

Funding

UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE CENTER: BPCAUL1RR024146 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$27.0M
UC Davis Clinical and Translational Science CenterKL2RR024144 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2006 to 2011
$3.1M
Regulation of Lipoprotein(a) Metabolism in Humans with Reference to EthnicityR01HL062705 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI BERGLUND, LARS F · 2000 to 2011
$2.9M
LIPOPROTEIN AND ADIPOSE TISSUE METABOLISM IN HIVR01HL065938 · NHLBI · UNIVERSITY OF CALIFORNIA DAVIS · PI BERGLUND, LARS F · 2000 to 2004
$1.6M
NCRR NIH HHS KL2 RR024144NCRR NIH HHS RR024146NCRR NIH HHS UL1 RR024146NHLBI NIH HHS HL 62705NHLBI NIH HHS HL 65938NHLBI NIH HHS R01 HL062705NHLBI NIH HHS R01 HL065938
6 · The paper itself

Abstract

purpose of reviewTo review the current scientific literature and recent clinical trials on HIV protease inhibitors and their potential role in the pathogenesis of lipodystrophy and metabolic disorders. RECENT

findingsHIV protease inhibitor treatment may affect the normal stimulatory effect of insulin on glucose and fat storage. Further, chronic inflammation from HIV infection and protease inhibitor treatment trigger cellular homeostatic stress responses with adverse effects on intermediary metabolism. The physiologic outcome is such that total adipocyte storage capacity is decreased, and the remaining adipocytes resist further fat storage. This process leads to a pathologic cycle of lipodystrophy and lipotoxicity, a proatherogenic lipid profile, and a clinical phenotype of increased central body fat distribution similar to the metabolic syndrome. SUMMARY: Protease inhibitors are a key component of antiretroviral therapy and have dramatically improved the life expectancy of HIV-infected individuals. However, they are also associated with abnormalities in glucose/lipid metabolism and body fat distribution. Further studies are needed to better define the pathogenesis of protease inhibitor-associated metabolic and body fat changes and their potential treatment.

Indexed as

AdipocytesAntiretroviral Therapy, Highly ActiveAtherosclerosisBody Fat DistributionFemaleGlucoseHIV InfectionsHIV Protease InhibitorsHumansIncidenceLipid MetabolismLipodystrophyMetabolic SyndromeObesityGlucoseHIV Protease Inhibitors

Identifiers

PMID20717021
PMCPMC3076638
OpenAlexW1970676567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.